Tempus Labs, Inc.
57 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded as renamed to Tempus AI, Inc. (2024)
0
Ending by 2030
Oct 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 23, 2026The maintenance fee for Artificial Intelligence Based Cardiac Event Predictor Systems and Methods (US 11,657,921) comes due Nov 23, 2026. Unpaid by May 24, 2027, it lapses early.
- 2 fees due Jan 11 to 18, 2027 · next Jan 11
- 1 fee due Feb 1, 2027The maintenance fee for Collaborative Artificial Intelligence Method and System (US 11,715,467) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
- 2 fees due Mar 12 to 26, 2027 · next Mar 12
- 1 fee due May 28, 2027The maintenance fee for Method and Process for Predicting and Analyzing Patient Cohort Response, Progression, and Survival (US 11,830,587) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US D897,991 | Speaker In force · High confidence | In force | High confidence | |
| US D905,662 | Speaker In force · High confidence | In force | High confidence | |
| US D937,243 | Speaker In force · High confidence | In force | High confidence | |
| US D941,264 | Speaker In force · High confidence | In force | High confidence | |
| US 11,367,508 | Systems and Methods for Detecting Cellular Pathway Dysregulation in Cancer Specimens In force · Medium confidence | In force | Medium confidence | |
| US 12,112,839 | Data Based Cancer Research and Treatment Systems and Methods In force · Medium confidence | In force | Medium confidence | |
| US 11,037,685 | Method and Process for Predicting and Analyzing Patient Cohort Response, Progression, and Survival In force · High confidence | In force | High confidence | |
| US 11,309,090 | Method and Process for Predicting and Analyzing Patient Cohort Response, Progression, and Survival In force · High confidence | In force | High confidence | |
| US 11,699,507 | Method and Process for Predicting and Analyzing Patient Cohort Response, Progression, and Survival In force · High confidence | In force | High confidence | |
| US 11,769,572 | Method and Process for Predicting and Analyzing Patient Cohort Response, Progression, and Survival In force · High confidence | In force | High confidence |
Also on record, not counted in the 24: 57 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
35 pending · 14 abandoned